Objective Boron neutron capture therapy (BNCT) is a noninvasive radiation therapy method for cancer treatment. In BNCT, 4-borono-2-[ 18 F]-fluoro-L-phenylalanine ( 18 F-FBPA) PET has been employed to estimate 10 B accumulation in target tumors and normal tissues if 10 B borono-L-phenylalanine ( 10 B-BPA) is used as a boron carrier. The purpose of the current study was to evaluate the total distribution volume (Vt) of 18 F-FBPA in normal organs of healthy volunteers by kinetic analysis and to estimate boron concentration in normal organs for the therapeutic dose of 10 B-BPA using obtained Vt values. Methods Six healthy volunteers were injected with 18 F-FBPA (3-5 MBq/kg), and 7 PET-CT scans were performed subsequently. 18 F-FBPA radioactivity in whole blood and plasma was measured before, and eight times after the injection. PET images were analyzed by PMOD software. Twelve volumetric regions of interest including the brain, heart, right lung, spleen, liver, parotid salivary glands, esophagus, stomach, pancreas, intestines, and bone marrow were drawn manually for each subject and analyzed with the Logan plot and two Ichise multilinear analyses (MA1 and MA2). The better model was defined by several goodnessof-fit parameters and residual distribution. After Vt values had been derived, boron concentration was estimated in ppm for the 10 B-BPA-fructose ( 10 B-BPA-fr) dose 30 g 1 and 2 h post-injection using Vt and interpolated plasma activity data.
Introduction
Boron neutron capture therapy (BNCT) is a rapidly growing area of medicine, at the junction of radionuclide diagnostics, nuclear physics, radiation therapy and, pharmacology. However, uptake of the boron-carrying molecules in target cells is heterogeneous [1] [2] [3] , depends on cellularity [4] , cell cycle phase [5, 6] , and many other factors. For effective treatment, the ratio of 10 B concentration in the tumor and its concentration in normal tissues (T/N ratio) should be more than 3:1, and the 10 B concentration in the target should be at least 15 μg/g [7, 8] . Therefore, to avoid adverse effects, it is necessary to know the concentration of the 10 B not only in tumor cells but also in normal tissues.
One of 10 B carriers in BNCT is 10 B 4-borono-L-phenylalanine ( 10 B-BPA). PET with 4-borono-2-[ 18 F]-fluoro-Lphenylalanine ( 18 F-FBPA) can be used for estimation of 10 B concentration in vivo [9] because 18 F-FBPA molecule has similar pharmacological behavior in normal tissues to that of 10 B-BPA [10, 11] .
There are several methods of evaluation of 10 B concentration in tumors and normal tissues through 18 F-FBPA PET. It could be estimated through the method proposed by Shimosegawa [12] in ppm. This method demonstrated a good correlation between predicted and actual boron concentrations in brain tissue. However, 18 F-FBPA injection protocol used in PET studies differs from the therapeutic protocol of 10 B-BPA administration, which could result in a discrepancy between the estimated and actual values of 10 B concentration.
The purpose of the current study was to evaluate 18 F-FBPA total distribution volume (Vt) in normal organs and tissues of healthy volunteers by non-compartmental, tracer reversible-binding graphical analysis of 18 F-FBPA PET images and to estimate boron concentration in normal tissues in human with obtained Vt values.
There are several studies performed in the laboratory of Nuclear Medicine Department of Osaka University concerning 18 F-FBPA properties and application in BNCT at present. Hanaoka et al. found a significant correlation between 10 B-BPA-fructose and 18 F-FBPA concentrations in an animal model. Shimosegawa et al. [12] could estimate boron concentration in ppm in normal tissues of healthy volunteers for 18 F-FBPA and therapeutic doses of 10 B-BPA-fructose complex ( 10 B-BPA-fr). Watabe et al. [13] proposed an approach to estimate boron concentration in absolute units form SUV of 18 F-FBPA-PET data using a rat model. Isohashi et al. [14] compared image-derived radioactivity and blood-sample radioactivity to be able to estimate boron concentration in the tumor before BNCT. 18 F-FBPA was prepared following the method of direct radio fluorination of 10 B-BPA, proposed by Ishiwata et al. [15] with a number of modifications, using the F-1 synthesizer (Sumitomo Heavy Industries, Tokyo, Japan).
Materials and methods

18
F-FBPA synthesis
First, elemental 18 F 2 gas was produced in 20 Ne(d,α) 18 F reaction and converted to 18 F-acetylhypofluorite in reaction with sodium acetate. 18 F-acetylhypofluorite was bubbled at a flow rate of 600 ml/min into 5 ml of trifluoroacetic acid containing 30 mg of 4-borono-L-phenylalanine, at room temperature. Then, trifluoroacetic acid was removed by passing N 2 under reduced pressure at a flow rate of 200 ml/min. Next, the residue was dissolved in 3 ml of 0.1% acetic acid, and the solution was passed through a high-performance liquid chromatography column YMC-Pack ODS-A (YMC, Kyoto, Japan) 20 × 150 mm, with the flow rate of 10 ml/min and 0.1% acetic acid as a mobile phase. Ultraviolet detector for wavelength 280 nm and radioactivity detector were applied for monitoring of the elution profile. After the 18 F-FBPA fraction was collected (retention time from 19 to 21 min), resultant 18 F-FBPA radiochemical purity was > 98%. The specific radioactivity was 44.1 ± 4.9 GBq/mmol.
The study protocol
The study involved 6 volunteers: 4 males and 2 females between ages 21 and 56 (average age 33 ± 16 years), and with the weight range of 48-66 kg (mean weight 61 ± 7 kg). None of the subjects had a prior history of any major diseases, drug or alcohol abuse, and cigarette smoking. All procedures of the study were explained in detail, and signed informed consent was collected from all subjects. The study was performed under the regulations of the institutional ethics committee for clinical research of Osaka University (No. 12113).
Subjects were prepared for the study by 4 h of fasting. After that, 18 F-FBPA (3-5 MBq/kg) was injected as a bolus into the left cubital vein. Subsequently, seven repeated wholebody PET scans from the top of the head to the mid-thigh were performed. The decay of radioactivity during the PET scan was corrected to the start time of the first scan. The data consisted of seven scans with 455 s acquisition time and the interval between scans of 45-46 s. 18 F-FBPA radioactivity in whole blood and plasma was measured at the background, 30 s, 1 min, 3 min, 5 min, 10 min, 20 min, 30 min, and 50 min using the PET camera and the well counter (Shimadzu Co, Kyoto, Japan), corrected mutually. The concentration of 18 F-FBPA metabolites in blood was also determined at the 20th and 50th minutes with mean values of 2.324% and 3.966% respectively, showing high stability. A wholebody CT scan (140 kV, 120-240 mAs) was performed after PET, for image fusion. Obtained images were reconstructed by Dynamic Row-Action Maximum Likelihood Algorithm (DRAMA) with an image matrix of 128 × 128, and a voxel size of 4.0 × 4.0 × 3.25 mm 3 . The axial field of view was 26 cm. All PET-CT studies were performed on Eminence SOPHIA SET-3000BCT/X scanner (Shimadzu Corporation) in the period from July 2013 to October 2013.
Image analysis
PET images were analyzed with PMOD biomedical image quantification software, build 3.601. Interpolation of the FBPA time-activity curves in plasma was carried out by the JMP Pro 13.0.0 software. Simple statistical calculations (mean, standard deviation values, and graphs) were carried out by the Microsoft Excel 2013 program.
Measurement of 18 F-FBPA accumulation was implemented through applying volumetric regions of interest (VOI) on 12 areas: the brain, heart, right lung, spleen, liver, parotid salivary glands on both sides, esophagus, stomach, pancreas, intestines, bone marrow. VOI setting was performed manually on each cross-sectional 18 F-FBPA PET image with CT images used as the reference. Tracer accumulation in bone marrow was evaluated by placing VOI on lumbar spine vertebrae bodies L1-L5. Tracer activity in both parotid glands was analyzed as one area. Vt quantification was carried out by two non-compartmental methods: the Logan plot graphical analysis using a single linear regression model, and two Ichise multilinear analysis (MA1 and MA2 models).
Following equations were employed for Vt calculation: Logan plot
Ichise analysis
where C(t) is the radioactivity concentration (kBq/ml) in VOI at time t (measured by PET); Cp(t) is the radioactivity concentration (kBq/ml) in plasma at time t (measured by the blood sampling corrected for metabolites); the slope (Vt) is the total distribution volume (ml/ml); b is the intercept; γ 1-4 are expressions including two-tissue model rate constants: [16, 17] . k 1 and k 2 represent the rate constants for the first tissue compartment, where k 1 characterizes the transport of the tracer from the blood to the tissue compartment, and k 2 characterizes the transport of the tracer to the opposite direction, from the first tissue compartment to the blood. And k 3 , k 4 are the rate constants in 2 tissue compartment model and represent inflow of the tracer in the second tissue compartment and its outflow from the second to the first tissue compartment.
An equilibration time t* (the time after which the plots of the equations become linear) with the maximal allowed error of the regression 1% was set automatically for the Logan plot
and for the Ichise MA1 and was fixed to 20 min for MA2 in all regions, since no equilibration is required for this model. The more suitable model had been selected on the ground of the Akaike Information Criterion (AIC) and reduced Chisquare (Chi-square) as goodness-of-fit parameters. Also, the coefficient of determination (R 2 ) was assessed, and residual distribution was analyzed and compared by the sum of squared residuals and the standard deviation of the residuals (Sy.x). 18 F-FBPA activity in plasma was used as the input function. Tracer concentration in kBq/ml was used for input function and tissue data import, under the assumption that the volume of 1 g of a tissue equals 1 ml. Subsequently, Vt values were calculated for each organ using the better model.
To estimate boron concentration for the conditions of the therapeutic BNCT protocol with 10 B-BPA-fructose injection dose 30 g (500 mg/kg; BW 60 kg) 1 and 2 h after 18 F-FBPA injection, first, the data set of plasma tracer activity in kBq/ ml was derived for each subject using plasma activity curves interpolated following tracer clearance data points with a bi-exponential model (Online Resource 1). Next, 18 F-FBPA tissue activity in kBq/ml was calculated in all VOI of each subject by the formula:
where T is the 18 F-FBPA concentration in an organ (kBq/ ml); P is the 18 F-FBPA concentration in plasma in a given time (kBq/ml), and V is the total distribution volume for that organ.
After that, 18 F-FBPA tissue concentrations were represented as molar concentrations:
where M is the 18 F-FBPA tissue molar concentration in mol/ml; T is the 18 F-FBPA activity tissue concentration in kBq/ml; S is the 18 F-FBPA mean specific radioactivity (4.41 × 10 10 kBq/mol).
Then, boron concentrations in ppm were calculated as follows, proceeding from the fact that one 18 F-FBPA molecule contains one 10 B atom, and averaged for each VOI:
where B is the boron concentration in ppm; MW B is the boron molecular weight (10 g/mol); M is 18 F-FBPA tissue molar concentration in mol/ml. Finally, boron concentration was estimated for the 10 B-BPA-fr therapeutic dose 30 g, with the formula devised by Shimosegawa et al. [12] .
(1) T = P * V,
where H is 10 B fraction for 10 B-BPA-fr dose 30 g in ppm;
B is the 10 B fraction of 18 F-FBPA (ppm); I is the mean 18 F-FBPA injected dose in grams (0.00102 g); MWfbpa is the 18 F-FBPA molecular weight (226.9 g/mol); MWbpa is the 10 B-BPA-fr molecular weight (389.3 g/mol).
Results
Tables 1, 2, and 3 display goodness of fit parameters employed to evaluate and compare the models. Multilinear models demonstrated relatively better goodness of fit than the single linear model, and the MA2 model appeared to be more accurate than MA1. AIC (the smaller the value, the better the fitting) showed more accurate fitting of the model curve for the MA2 model in all regions ( Table 4 .
Vt showed greater variability of the results between the subjects for the MA2 model, comparing to the MA1 model and the Logan plot, probably because of the constant t* 20 min for all VOIs (mean SD 0.8 for MA1 and the Logan plot vs. 0.12 for MA2). The highest average Vt value was observed in the pancreas, followed by liver, parotid glands, esophagus, stomach, heart, bone marrow, intestines, spleen, brain, and lung in descending order. In general, Vt values of 18 F-FBPA in selected organs and tissues were consistent with its mean activity concentration in the washout phase. Data is represented in Table 4 and Fig. 1 .
Estimated boron concentrations for the therapeutic 10 B-BPA-fructose administration protocol at 1 and 2 h are presented in Table 5 . It showed the maximal value in the pancreas (14.0 ± 1.9 ppm 1 h after, and 5.7 ± 1.7 ppm, 2 h after the 18 F-FBPA administration) and the minimal value in the right lung (2.4 ± 0.3 ppm 1 h, and 1.0 ± 0.3 ppm 2 h post-injection). 
Discussion
In the current work, we estimated Vt of 18 F-FBPA in healthy volunteers using single linear (Logan graphical analysis) and multilinear (Ichise MA1; MA2) models for reversibly binding tracers. This approach has several advantages, such as good reproducibility of the results in an individual patient or between the patients. Also, boron concentration could be estimated at any time point, after the equilibrium state between the influx of the tracer into the tissue compartment and its efflux to the plasma is reached.
The volume of distribution represents the ratio of the tracer concentrations in the target tissue (Ct) and plasma (Cp) at equilibrium or steady-state: Vt = Ct/Cp. Thereby knowing tracer concentration in plasma at equilibrium and Vt value for the certain tissue, Ct value for that tissue can be calculated. It is also independent of the tracer administration protocol in case if the constant ratio of tracer concentrations in blood and tissues is achieved [18] , and could be applied to any reversibly binding tracer. 18 F-FBPA uptake in normal tissues is reversible, it is not trapped inside the cells nor incorporated into proteins, and rapidly washed out from the tissues [10] , and thus dynamic equilibrium between plasma and tissue 18 F-FBPA concentrations is reached with time. Vt values obtained for 18 F-FBPA could be applied for 10 B-BPA, so finally tissue 10 B-BPA concentration could be derived from its plasma concentration.
Initially, only the single linear analysis had been selected for its relative computational simplicity. However, the Logan plot was found to have low compatibility of the model and actual curves. It tended to show better fit with t* shifted manually to the later time points, partially due to the reduction of available data and lower variability. If t* value was changed to 33 min, where the model fit was acceptable, the remaining 3 data points were not sufficient to evaluate residual distribution adequately. Besides, stabilization of γ-intercept, that should become constant after the time t*, couldn't be achieved due to limited data points. For that reason, multilinear models Ichise MA1 and MA2 had been chosen additionally.
Ichise multilinear analysis being a derivate of the Logan plot analysis provides reduced bias for both one-tissue 18 F-FBPA activity in all selected VOIs in the washout phase (from the seventeenth minute), measured in kBq/ml and averaged for all subjects (n = 6). The highest value is detected in the pancreas, and the lowest in the lung. The mean activity is consistent with Vt values and two-tissue compartment models, especially in case of region-of-interest based parameter estimation. MA1 is independent of t* only for a 1-tissue model, but as the Logan plot, it requires it for a 2-tissue model. MA2 is especially interesting because it does not require definite t* and could be applied for 1-tissue and 2-tissue models, and suitable for radiotracers with slow kinetics [17] . Brain time-activity curve had significantly different pattern compared to other organs (Fig. 2) , with the gradual increase of radioactivity up to thirty-fourth minute and following slow decrease until the end of the study. Probably it is caused by different pharmacokinetics of the tracer due to high Large Amino Acid Transporter type 1 (LAT1) expression in the blood-brain barrier [19] . Thereby Ichise MA2 could be the optimal model for this area.
Maximal Vt value did not exceed 1.08 ml/ml (in the pancreas). This value is much lower than Vt values for tumors, that could be found in literature for animal tumor model [20] , or derived from published rate constants for human and rat glioma [21, 22] , reflecting lower k 1 /k 2 ratio in normal tissues, that in turn could be explained by differences in expression of amino acid transporters, between normal and tumor cells and their affinity to the ligand. In tumors LAT1 and ATB 0,+ upregulation has been found, and these transporters are responsible for 10 B-BPA and 18 F-FBPA uptake in tumor cells [23] . LAT2, which is expressed in normal cells, has lower affinity for 18 F-FBPA, comparing to LAT1 and shows lower 18 F-FBPA transportability [24] .
In addition, mean Vt appeared to be lower than 1 for all selected organs, suggesting tracer concentration in normal tissues to be lower than that in plasma, after the equilibration time. The highest uptake is seen in the pancreas, and the lowest is seen in the lung. Each time point matches the middle of each scan. In the brain continuous increase of radioactivity up to thirty-forth minute and slow decrease until the end of the study is observed There are several factors that could influence the accuracy of acquired Vt values. Areas selected for analysis included functionally and histologically different tissues. These tissues contain boron compound not only in the interstitium but also in blood vessels, as well as chyme and gases in the hollow organs and air in the lungs, which affects the accuracy of boron concentration measurements. The influence of such factors was not evaluated in the current study.
Due to the superimposition of the pancreas VOI and area of high tracer accumulation in the left kidney, the tail of the pancreas was partially excluded from the analysis.
Also, 18 F-FBPA metabolization with the detachment of the boron atom takes place to some degree, most likely due to hepatic enzymes' activity [25] , thereby contributing to the bias of measurements.
System L is the transporting system responsible for 10 B-BPA uptake in normal tissues [26] , and LAT2 is l-amino acid transporter mainly expressed in normal cells [23, 27] . However, 18 F-FBPA had lower affinity and transportability to LAT2 in comparison with 10 B-BPA [24] , which could also have an impact on the results.
It was found that N/B ratios for 10 B-BPA and 19 F labeled FBPA differed depending on the administration protocol and were lower for the continuous infusion group comparing to the single-injection group [11] . Although the result is obtained in the animal experiment and compounds were administrated subcutaneously, whereas intravenous infusion is commonly used in humans, it still can cause the discrepancy between 10 B concentration values depending on the protocol features.
In another study of 10 B-BPA pharmacokinetics, biphasic exponential clearance of 10 B-BPA concentration from the blood after the peak is reached was reported, and the time lag between the 10 B-BPA blood and tissue concentrations was suggested [28] . The equilibrium state between these concentrations will be achieved during the late phase of the clearance. However, if neutron irradiation takes place before the late phase equilibrium reached, disagreement between actual and estimated values could occur.
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